Deals and Financings
• InventisBio of Shanghai closed a $70 million Series C financing to develop its portfolio of 30 novel therapeutics for cancer and metabolic diseases;
• BGI Genomics of Shenzhen formed a $50 million partnership with Natera to commercialize Natera's Signatera™ MRD (minimal residual disease) test in China;
• Shanghai's Newsoara acquired Asia rights to develop a TaiwanJ treatment for nonalcoholic steatohepatitis (NASH) in a $26 million agreement;
• Shanghai Changren Information Technology, a China IT health management company, raised $15 million in a Series A funding round;
• Yunhu Technology of Hangzhou secured "tens of millions RMB" in a Series A+ financing company for its China primary medical services internet platform;
• Chengdu's HitGen will collaborate with Sun Pharma Advanced Research Company of India to discover small molecule leads;
• CASI, a US-Beijing pharma, out-licensed China marketing rights for Evomela® (melphalan hydrochloride for injection) in China to CR Guokang;
Company News
• Dr. Zhengqing Li became Ascletis' CMO and President of R&D Greater China after eight years as General Manager of MSD's R&D Center China;
Trials and Approvals
• CStone Pharma (Suzhou) was approved to start a China Phase I trial of its histone deacetylase 6 (HDAC6) selective inhibitor;
• CARsgen, a Shanghai biopharma, was approved to start China clinical trials of its fully human BCMA CAR-T cell therapy in patients with multiple myeloma.
Stock Symbols: (SHZ: 300696) (NSDQ: NTRA) (BSE: 532872) (NSDQ: CASI) (HK: 2616)
Share this with colleagues: